Navigation Links
Optimer Pharmaceuticals to Present at March 2011 Investor Conferences

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Citi 2011 Global Health Care Conference on Thursday, March 3, 2011 at 10:00 a.m. Eastern Time at the Hilton New York Hotel in New York City.
  • Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011 at 4:45 p.m. Eastern Time at The Boston Marriott Copley Place in Boston.

  • (Logo:

    Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at  Replays of these presentations will be available at the same location for 30 days following the meeting.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    2. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    3. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
    4. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
    5. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    6. Optimer Pharmaceuticals Announces Key Additions to Management Team
    7. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
    8. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
    9. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
    10. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
    11. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    Post Your Comments:
    (Date:12/1/2015)... Germany , December 1, 2015 ... manufacturer of eye and gaze tracking solutions, today announced ... eye trackers as a component of its revolutionary new ... sight, and medical and performance issues in patients. The ... SMI,s mass-market-ready eye tracking platform, which is ready to ...
    (Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
    (Date:12/1/2015)... , Dec. 1, 2015 Research and ... of the "2016 Global Enteric Disease Testing ... Salmonella, Shigella, Vibrio, Yersinia--France, Germany, Italy, Japan, Spain, ... Japan . --> ... The report is based on a combination ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... San Diego, CA (PRWEB) , ... December 01, ... ... simplicity and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of ... Ease® mobile imaging results enhancements at the Radiological Society of North America (RSNA) ...
    (Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
    (Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech ... through membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, ... has spent a significant amount of time in Sweden since joining PartnerTech based ...
    (Date:12/1/2015)... , ... December 01, 2015 , ... ... on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This ... patient care experience, and propose exciting enhancements to the medical landscape. , The ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
    Breaking Medicine News(10 mins):